|Dr. Shankar Musunuri M.B.A., Ph.D., MBA||Founder, Chairman & CEO||N/A||N/A||1964|
|Dr. Uday B. Kompella||Founder & Director||N/A||N/A||N/A|
|Mr. Sanjay S. Subramanian||Chief Financial Officer||N/A||N/A||1976|
|Dr. Rasappa Arumugham||Chief Scientific Officer||N/A||N/A||1952|
|Ms. Kelly A. Beck M.B.A., P.M.P., SPHR||VP of Investor Relations & Admin.||N/A||N/A||N/A|
Ocugen, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. The company offers an ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules, as well as targets a range of retinal and ocular surface diseases. Its pipeline includes OCU400 and OCU410 for the treatment of inherited retinal disorders; OCU200 for the treatment of wet-AMD, DME, and diabetic retinopathy; OCU100 for retinitis pigmentosa; and OCU300, which is in Phase III clinical trial for the treatment of ocular graft versus host diseases. The company has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing. Ocugen, Inc. is based in Malvern, Pennsylvania.
Ocugen, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.